Condition
Newly Diagnosed Peripheral T-cell Lymphoma
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Unknown3
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05976997Phase 2UnknownPrimary
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
NCT05931263Phase 3RecruitingPrimary
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
NCT05896813Not ApplicableUnknownPrimary
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
NCT03631862Phase 4UnknownPrimary
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
Showing all 4 trials